By Cristina Roca

Novartis AG said late Friday that the U.S. Food & Drug Administration has approved Scemblix for two indications in chronic myeloid leukemia.

The Swiss pharmaceutical company said the treatment received accelerated approval for one indication and full approval for a second indication. This means continued approval for the first indication may be contingent on confirmatory evidence.

Write to Cristina Roca at cristina.roca@wsj.com

(END) Dow Jones Newswires

November 01, 2021 02:20 ET (06:20 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Novartis Charts.